'Tevogen Revenue Forecast of $1 B in Launch Year, Cumulative 5-Year Estimate $10-14 B'

 Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

https://www.globenewswire.com/news-release/2024/10/17/2964973/0/en/Tevogen-Bio-Oncology-Reports-Top-Line-Revenue-Forecast-of-1-Billion-in-Launch-Year-and-Cumulative-5-Year-Estimate-Between-10-Billion-and-14-Billion-Forecasts-for-Non-Oncology-Thera.html